Neuraxpharm’s Brand Evolution and Global Expansion
The organization known for its focus on central nervous system disorders has undergone a series of brand and name shifts to reflect a unified corporate identity. The production hub previously operating under a Lesvi Laboratories banner will now be referred to as Neuraxpharm Medicines. This change signals a complete integration of the facility into the Neuraxpharm group, aligning manufacturing capabilities with the broader corporate umbrella and signaling that the facility serves both in house brands and partner companies across national and international markets. Lesvi Laboratories, established in 1979 as part of Invent Medicines, later joined Neuraxpharm Germany in a strategic merger. With a workforce of over 280, the facility specializes in solid oral dosage forms. Over the past six years, production output has increased by 56 percent, and a capital investment of 30 million euros has modernized the site to meet current production standards.
Ramón Sitges, the facility manager, commented on the transition, noting that the name change to Neuraxpharm Medicines marks the full integration of the site within the group. He emphasized that the company’s ability to develop and manufacture high quality products remains a top priority. The move also represents a commitment to stronger coordination with the workforce and enhanced service delivery for the group and its partners.
Earlier in the year, Neuraxpharm completed the acquisition of two established product portfolios from Sanofi, expanding its CNS offerings with 17 molecules and 38 brands marketed in more than 50 countries. The company also agreed to divest Inke to Keensight Capital. In the previous year, Neuraxpharm expanded into digital medical devices and digital health through licensing agreements related to its first orphan indication in the central nervous system. The organization has further extended its geographic footprint by increasing activities in Greece, the Netherlands, and the Benelux region with the establishment of Neuraxpharm Belgium, serving Belgium and Luxembourg. Overall, Neuraxpharm employs more than 1,000 people and maintains a direct presence in 20 countries, with additional reach through partners in 60 countries, reflecting a broad, interconnected global operation. This information is based on corporate communications from Neuraxpharm.